ClinicalTrials.gg
Drug

Daraxonrasib clinical trials

Also written RMC-6236.

studies test it
14
open now
13
in phase 3
5
first study started
2022

How each study uses daraxonrasib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the daraxonrasib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
26 Aug 2026 · RASONQUE · NDA 220910 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Daraxonrasib
10

Development codes

RMC-6236
8

Studies by the year they started

11 studies that test it; most in 2026 (4); 3 more planned to start later

Studies that test daraxonrasib, by start year
YearStudies
20221
20231
20243
20252
20264

By phase

A phase 1/2 study counts in both.

Phase 1
7
Phase 2
8
Phase 3
5

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 10 · Other 4

Revolution Medicines, Inc. (10) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · National Health Research Institutes, Taiwan (1) · Dana-Farber Cancer Institute (1) · Children's Oncology Group (1)

Often tested with

Tested in the same studies.

Zoldonrasib (3) · Gemcitabine (2) · Albumin-Bound Paclitaxel (2) · Paclitaxel (2) · Elironrasib (2) · Cetuximab (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 2

Studies that test daraxonrasib.

Studies

Open first, then newest update. How each study uses daraxonrasib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 14

Behind its US label · 1 — the studies the FDA label of RASONQUE describes

From the Clinical Studies section of RASONQUE (2026-08), as openFDA has it. A study the site does not hold is left out.

Given beside what is tested · 7 — daraxonrasib is usual care or a partner of the new treatment

What changed recently

From the registry's own updates since Oct 18, 2026.

Newly registered2

Codes

What other systems call daraxonrasib · ClinicalTrials.gg INT002100

  • MeSH (NLM) C000731071daraxonrasibOne source NLM
  • UNII (FDA) B6T47Y2UAPDARAXONRASIBConfirmed FDA, NLM, Wikidata
  • Wikidata Q136659312daraxonrasibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C188048DaraxonrasibOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.